Q-omics provides the consensus-scored C19orf33 profile across patient tissues and cancer cell-line models. C19orf33 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, C19orf33 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, C19orf33 protein abundance shows 16,127 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, THCA, and HNSC as cancer lineages where C19orf33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf33 survival associations across molecular data types. C19orf33 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf33 RNA expression–survival associations across cancer types. High C19orf33 expression shows unfavorable associations in LUAD, OV, PAAD, HNSC and UVM, but favorable associations in KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for C19orf33 RNA expression.
This table summarizes C19orf33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for C19orf33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf33 shows lower tumor expression in COAD and KICH and higher tumor expression in THCA, KIRC, KIRP and BLCA. The THCA box plot shows higher C19orf33 RNA expression in tumor versus normal tissue (log2 FC = +3.141, t-test p < 0.001).
This table shows molecular features associated with C19orf33 in patient tissues and cancer cell lines. In patient samples, C19orf33 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
